Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission

Mitja Jevnikar, Olivier Sanchez, Richard Chocron, Marc Andronikof, Maurice Raphael, Olivier Meyrignac, Laure Fournier, David Montani, Benjamin Planquette, Mary Soudani, Athénaïs Boucly, Jeremie Pichon, Mariana Preda, Antoine Beurnier, Sophie Bulifon, Andrei Seferian, Xavier Jaïs, Olivier Sitbon, Laurent Savale, Marc Humbert, Florence Parent
European Respiratory Journal 2021 58: 2100116; DOI: 10.1183/13993003.00116-2021
Mitja Jevnikar
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Sanchez
4AP-HP, Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, Paris, France
5INSERM UMR-S 1140; Paris, France and INNOVTE, St-Etienne, France
6Université Paris Descartes, Faculty of Medicine, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Chocron
6Université Paris Descartes, Faculty of Medicine, Paris, France
7AP-HP, Service d'Urgence, Hôpital Européen Georges Pompidou, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Chocron
Marc Andronikof
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
8AP-HP, Service d'Urgenc, Hôpital Antoine Béclère, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurice Raphael
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
9AP-HP, Service d'Urgence, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Meyrignac
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
10AP-HP, Service de Radiologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laure Fournier
6Université Paris Descartes, Faculty of Medicine, Paris, France
11AP-HP, Service de Radiologie, Hôpital Européen Georges Pompidou, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Montani
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Montani
Benjamin Planquette
4AP-HP, Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, Paris, France
5INSERM UMR-S 1140; Paris, France and INNOVTE, St-Etienne, France
6Université Paris Descartes, Faculty of Medicine, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Soudani
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
12AP-HP, Service de gériatrie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athénaïs Boucly
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Pichon
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Preda
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Beurnier
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
13AP-HP, Service de physiologie et d'explorations fonctionnelles respiratoires (CRISALIS/F-CRIN network), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Bulifon
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrei Seferian
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Jaïs
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Sitbon
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Sitbon
Laurent Savale
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Savale
Marc Humbert
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
Florence Parent
1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There is a high prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission https://bit.ly/3reaLjv

To the Editor:

A high prevalence of venous thromboembolism (VTE) has been reported during intensive care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID-19) [1, 2]. In most cases, the diagnosis of pulmonary embolism (PE) was incidental as patients underwent computed tomography pulmonary angiography (CTPA) for aggravation of their respiratory condition. Higher mortality is also described in patients with high D-dimer levels suggesting that VTE complication may contribute to unfavourable prognosis [3, 4]. Even though, prevalence of thromboembolic complications during ICU hospitalisation seems to be high, the prevalence of pulmonary embolism at hospital admission for COVID-19 is unknown and may be underestimated.

In the present research letter, we report a prospective multicentre study that evaluates the pulmonary embolism prevalence in patients admitted for COVID-19, at the time of admission in three tertiary hospitals, Bicêtre Hospital and Béclère Hospital, University Paris-Saclay, and European Georges Pompidou Hospital, Paris University (Paris, France).

All consecutive adult outpatients hospitalised between April 15, 2020, to May 23, 2020, with a diagnosis of COVID-19 were included and underwent a CTPA, if not contraindicated, at the time of hospital admission. Patients with renal failure (<30 mL·min−1 of clearance) or contraindications to iodinated contrast material were excluded from the study. COVID-19 diagnosis was confirmed by the presence of positive Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR and/or typical computed tomography abnormalities (i.e. ground-glass opacities and/or consolidation in the lung periphery) [5, 6]. Hospital admission was decided by the clinician in charge at the emergency department of each participating hospital according to clinical criteria.

The computed tomography patterns of COVID-19 pneumonia and the presence of pulmonary embolism were analysed locally by a senior radiologist and a pulmonologist. Patients without pulmonary embolism received prophylactic anticoagulation during hospitalisation, according to local practice.

Patients were prospectively followed-up for three months or until death, by a telephone interview within 3 months after admission.

Performing systematic CTPA was in accordance with the multidisciplinary medical crisis team for COVID-19 and all patients received oral information about data collection. Upon consent, data were recorded in an anonymous database registered to the National Commission on Informatics and Liberty (n°26750045200441). The study was been approved by the CERAPHP Centre (Comité d'éthique de la recherche APHP Centre; IRB registration: #00011928).

Quantitative data are expressed as median (interquartile range) and qualitative data are expressed as n (%). The prevalence of pulmonary embolism was calculated, and the 95% confidence intervals were determined. Comparisons between groups were performed using the independent student's t-test if the distribution of variables was normal and by the Wilcoxon test if not normally distributed. A multivariable logistic regression model adjusted for age and sex was calculated for significant results (p<0.05). Categorical variables were compared using the Chi-squared test for independence. XLSTAT (Addinsoft, 2019, Long Island, NY, USA) and Graphpad prism (GraphPad Software, La Jolla, CA, USA) software were used. A p-value of <0.05 was considered statistically significant.

During the study period, 135 consecutives outpatients were hospitalised for COVID-19 at the three participating hospitals. Among them, 29 (21.5%) were excluded from the study, mainly due to contraindications for iodinated contrast administration (n=12), inability to understand oral information (n=7) and screening failure (n=10). Of the 106 included patients, five (4.7%) patients were directly admitted to an ICU.

Overall, pulmonary embolism was diagnosed in 15 out of 106 patients giving a prevalence of 14.2% (95% CI 7.5–20.8). Among the five patients directly admitted in ICU, one had a confirmed pulmonary embolism at admission. Table 1 summarises the characteristics of included patients and the chest computed tomography scan features. CTPA was well tolerated with no aggravation of renal function (n=87; p=0.52) and only one complication (0.9%) was reported due to iodinated material extravasation with no severe consequences.

View this table:
  • View inline
  • View popup
TABLE 1

Baseline characteristics and comparison between patients with pulmonary embolism and patients without pulmonary embolism

Patients with confirmed pulmonary embolism on admission had significantly higher D-dimer median concentrations, more often needed oxygen administration in the emergency department and had longer median time from symptoms to hospital admission as compared to patients without pulmonary embolism. In multivariable analysis, only high D-dimer median concentrations (OR 1.001 (1–1.002)) and time from symptoms to hospital admission (OR 1.103 (1.019–1.193)) were independently associated with pulmonary embolism.

No significant difference was observed for computed tomography staging of COVID-19 lung involvement between patients with and without pulmonary embolism (p=0.85) and five (33.3%) out of 15 patients had pulmonary embolism in the same location as COVID-19 pneumonia. Pulmonary embolism was lobar in seven (46.7%), segmental in six (40%) and sub-segmental in two (13.3%) cases, respectively. Right ventricular/left ventricular diameter ratio>1 was observed in five patients (33.3%).

During the time of hospitalisation, 15 (16.5%) out of 91 patients had a repeated CTPA for clinical worsening without identification of any new pulmonary embolisms. Patients without pulmonary embolism at admission received standard VTE prophylaxis by enoxaparin 4000 IU·day−1. In ICU patients, obese patients (BMI>35) and patients with high level of biological inflammation (D-dimer level greater than 1000 μg·L−1) high-intensity VTE prophylaxis by Enoxaparin 4000 IU/12 h was used (or enoxaparin 6000 IU·12 h−1 in case of weight greater than 120 kg). After discharge, standard VTE prophylaxis was prolonged for 2–4 weeks in cases of persistently impaired mobility or persistently high levels of biological inflammation. 14 (13.2%) out of 106 patients died during hospitalisation. Death was related to COVID-19 in 13 (93%) cases and related to pulmonary embolism in only one (7%) case. The median (interquartile range) interval between admission and death was 11 days (6–29). Patients who died were significantly older (median 83 years (79.5–89.5) (p=0.001)) and more of them had severe, very severe or critical features of COVID-19 pneumonia on CTPA (p=<0.001) at admission (table 1).

Hospital mortality in patients with confirmed pulmonary embolism on admission was four (26.6%) out of 15 and was not statistically different compared to hospital mortality of the group without pulmonary embolism 10 (11.0%) out of 91 (p=0.09), which might be primarily driven by the small study size. At 3 months, no patients were lost to follow-up and seven additional deaths occurred for a total mortality rate of 21 (19.8%) out of 106. Of these seven deaths, six were due to comorbidities and one was of unknown cause in an 85-year-old woman. No VTE recurrence occurred after hospital discharge in survivors.

This present study showed a prevalence of pulmonary embolism of 14.2% (95% CI 7.5–20.8) at the time of hospital admission for COVID-19. In line with previous reports, our study suggests that pulmonary embolism is a common complication among COVID-19 patients [1, 2]. However, this is the first study to describe the prevalence of pulmonary embolism at hospital admission.

Although a high prevalence of pulmonary embolism is reported in ICU (20.6–27%) and at conventional wards (8.3%) in patients with COVID-19, all these studies, the reported prevalence of pulmonary embolism is potentially biased since CTPA was only performed in COVID-19 patients with clinical aggravation and/or with clinical suspicion for pulmonary embolism and CTPA might not have been performed in intubated patients with a severe clinical course [1, 7–9]. In contrast, in our study, CTPA was performed routinely on admission regardless of whether pulmonary embolism was clinically suspected or not.

During follow up, no other pulmonary embolisms were diagnosed, suggesting that looking for pulmonary embolism at the time of admission, and using a prophylactic anticoagulant treatment in the absence of pulmonary embolism, is safe and prevents new pulmonary embolism during the in-hospital period and 3-month follow-up period.

One of the study limitations is the relatively small number of COVID-19 admitted patients. Indeed, our study started after the lockdown setting of our region that fortunately reduced the number of COVID-19 hospitalisation. Additionally, 21.5% of patients were excluded from the study, mostly due to contraindications to iodinated contrast injection or inability to understand verbal information about the study due to dementia. Lastly, there were protocol violations because D-dimer tests were not done in eight patients, two of whom had acute pulmonary embolism confirmed on CTPA. Large multicentre cohort studies are needed to confirm these data and explore the reasons why SARS-CoV-2 predisposes to VTE events, as no other respiratory viruses are known to do this [10–13].

In conclusion, this prospective study reported a high prevalence of pulmonary embolism in patients with COVID-19 at time of hospital admission. For this reason, we support CTPA exams on hospital admission in COVID-19 patients requiring supplemental oxygen, having high D-dimer concentrations or long history of COVID-19 symptoms, if no contraindicated.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-00116-2021.Shareable

Footnotes

  • Conflict of interest: M. Jevnikar has nothing to disclose.

  • Conflict of interest: O. Sanchez has nothing to disclose.

  • Conflict of interest: R. Chocron has nothing to disclose.

  • Conflict of interest: M. Andronikof has nothing to disclose.

  • Conflict of interest: M. Raphael has nothing to disclose.

  • Conflict of interest: O. Meyrignac has nothing to disclose.

  • Conflict of interest: L. Fournier has nothing to disclose.

  • Conflict of interest: D. Montani has nothing to disclose.

  • Conflict of interest: B. Planquette has nothing to disclose.

  • Conflict of interest: M. Soudani has nothing to disclose.

  • Conflict of interest: A. Boucly has nothing to disclose.

  • Conflict of interest: J. Pichon has nothing to disclose.

  • Conflict of interest: M. Preda has nothing to disclose.

  • Conflict of interest: A. Beurnier has nothing to disclose.

  • Conflict of interest: S. Bulifon has nothing to disclose.

  • Conflict of interest: A. Seferian has nothing to disclose.

  • Conflict of interest: X. Jaïs has nothing to disclose.

  • Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion Pharmaceuticals and MSD, personal fees from Acceleron Pharmaceuticals, Gossamer Bio and Ferrer, grants and personal fees from Bayer, grants from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: L. Savale has nothing to disclose.

  • Conflict of interest: M. Humbert reports grants and personal fees from Actelion, personal fees from GSK and Merck, outside the submitted work.

  • Conflict of interest: F. Parent has nothing to disclose.

  • Received November 7, 2020.
  • Accepted February 28, 2021.
  • Copyright ©The authors 2021.
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Klok FA,
    2. Kruip MJHA,
    3. van der Meer NJM, et al.
    Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147. doi:10.1016/j.thromres.2020.04.013
    OpenUrlCrossRefPubMed
  2. ↵
    1. Helms J,
    2. Tacquard C,
    3. Severac F, et al.
    High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089–1098. doi:10.1007/s00134-020-06062-x
    OpenUrlCrossRefPubMed
  3. ↵
    1. Frydman GH,
    2. Streiff MB,
    3. Connors JM, et al.
    The potential role of coagulation factor Xa in the pathophysiology of COVID-19: a role for anticoagulants as multimodal therapeutic agents. TH Open Companion J Thromb Haemost 2020; 4: e288–e299.
    OpenUrl
  4. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
    OpenUrlCrossRefPubMed
  5. ↵
    1. Xu X,
    2. Yu C,
    3. Qu J, et al.
    Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020; 47: 1275–1280. doi:10.1007/s00259-020-04735-9
    OpenUrlCrossRefPubMed
  6. ↵
    1. Revel M-P,
    2. Parkar AP,
    3. Prosch H, et al.
    COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol 2020; 30: 4903–4909. doi:10.1007/s00330-020-06865-y
    OpenUrlPubMed
  7. ↵
    1. Poissy J,
    2. Goutay J,
    3. Caplan M, et al.
    Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142: 184–186. doi:10.1161/CIRCULATIONAHA.120.047430
    OpenUrlPubMed
    1. Fauvel C,
    2. Weizman O,
    3. Trimaille A, et al.
    Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J 2020; 41: 3058–3068. doi:10.1093/eurheartj/ehaa500
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lodigiani C,
    2. Iapichino G,
    3. Carenzo L, et al.
    Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9–14. doi:10.1016/j.thromres.2020.04.024
    OpenUrlCrossRefPubMed
  9. ↵
    1. Varga Z,
    2. Flammer AJ,
    3. Steiger P, et al.
    Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418. doi:10.1016/S0140-6736(20)30937-5
    OpenUrlCrossRefPubMed
    1. Magro C,
    2. Mulvey JJ,
    3. Berlin D, et al.
    Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res J Lab Clin Med 2020; 220: 1–13.
    OpenUrl
    1. Ackermann M,
    2. Verleden SE,
    3. Kuehnel M, et al.
    Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128. doi:10.1056/NEJMoa2015432
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bunce PE,
    2. High SM,
    3. Nadjafi M, et al.
    Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 52: e14–17. doi:10.1093/cid/ciq125
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 58 Issue 1 Table of Contents
European Respiratory Journal: 58 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission
Mitja Jevnikar, Olivier Sanchez, Richard Chocron, Marc Andronikof, Maurice Raphael, Olivier Meyrignac, Laure Fournier, David Montani, Benjamin Planquette, Mary Soudani, Athénaïs Boucly, Jeremie Pichon, Mariana Preda, Antoine Beurnier, Sophie Bulifon, Andrei Seferian, Xavier Jaïs, Olivier Sitbon, Laurent Savale, Marc Humbert, Florence Parent
European Respiratory Journal Jul 2021, 58 (1) 2100116; DOI: 10.1183/13993003.00116-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission
Mitja Jevnikar, Olivier Sanchez, Richard Chocron, Marc Andronikof, Maurice Raphael, Olivier Meyrignac, Laure Fournier, David Montani, Benjamin Planquette, Mary Soudani, Athénaïs Boucly, Jeremie Pichon, Mariana Preda, Antoine Beurnier, Sophie Bulifon, Andrei Seferian, Xavier Jaïs, Olivier Sitbon, Laurent Savale, Marc Humbert, Florence Parent
European Respiratory Journal Jul 2021, 58 (1) 2100116; DOI: 10.1183/13993003.00116-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Long COVID symptoms, from an imaginary condition to a recognised syndrome
  • Erythrocytes are altered in PAH
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
Show more Agora

Research letters

  • Erythrocytes are altered in PAH
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
  • NTM-PD incidence among elderly patients with bronchiectasis
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society